{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:09:34Z","timestamp":1761718174861,"version":"3.28.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[1998,12,1]],"date-time":"1998-12-01T00:00:00Z","timestamp":912470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The purpose of this study was to stabilize transdermal drug-delivery systems (TDDS) highly loaded with sex steroids against recrystallization of drugs during storage. To facilitate the selection of potential crystallization inhibitors a drug-excipient interaction test was also established.<\/jats:p>\n               <jats:p>Analysis of the thermal behaviour of 1:1 steroid-excipient mixtures by differential scanning calorimetry (DSC) revealed that oestradiol and gestodene interact strongly with silicone dioxide and povidones, e.g. povidone K12. The addition of povidone K12 to polyacrylate-based matrix TDDS containing either 3% oestradiol or 2% gestodene resulted in stable systems which did not recrystallize during storage at 25\u00b0C for more than 5 years. Significant recrystallization was, on the other hand, observed in non-stabilized reference patches even after 1 to 2 months storage.<\/jats:p>\n               <jats:p>The DSC screening model proved very effective for selection of inhibitors of the crystallization of sex steroids in matrix TDDS. The crystallization inhibitor approach is a highly versatile stabilization tool for matrix patches containing high concentrations of sex steroids.<\/jats:p>","DOI":"10.1111\/j.2042-7158.1998.tb03357.x","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T15:40:19Z","timestamp":1302709219000},"page":"1343-1349","source":"Crossref","is-referenced-by-count":40,"title":["Selection and Use of Crystallization Inhibitors for Matrix-type Transdermal Drug-delivery Systems Containing Sex Steroids"],"prefix":"10.1093","volume":"50","author":[{"given":"Ralph","family":"Lipp","sequence":"first","affiliation":[{"name":"Drug-Delivery Systems , Schering AG, D-13342 Berlin,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1998,12,1]]},"reference":[{"volume-title":"Dermatological Formulations","year":"1983","author":"Barry","key":"2024103110030301300_cit1"},{"key":"2024103110030301300_cit2","first-page":"891","article-title":"Transdermal hormone replacement adhesives","volume":"24","author":"Carring","year":"1997","journal-title":"Proc. Int. Symp. Contr. Rel. Bioact. Mater."},{"volume-title":"Einflu\u03b2 von Permeationsf\u00f6rderern auf die Freisetzung von Gestoden aus Transdermalen Therapeutischen Systemen","year":"1994","author":"Hartisch","key":"2024103110030301300_cit3"},{"key":"2024103110030301300_cit4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0022-0248(95)00301-0","article-title":"The effect of structurally related substances on the nucleation kinetics of paracetamol (acetaminophen)","volume":"156","author":"Hendriksen","year":"1995","journal-title":"J. Cryst. Growth"},{"key":"2024103110030301300_cit5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0022-0248(97)00328-X","article-title":"Supersaturation dependence of crystal growth in solutions in the presence of impurity","volume":"182","author":"Kubota","year":"1997","journal-title":"J. Cryst. Growth"},{"key":"2024103110030301300_cit6","doi-asserted-by":"crossref","first-page":"S-213","DOI":"10.1023\/A:1018995005775","article-title":"X-ray structure determinations of crystals grown in transdermal delivery systems containing estradiol or gestodene","volume":"11","author":"Lipp","year":"1994","journal-title":"Pharm. Res."},{"key":"2024103110030301300_cit7","first-page":"15357w","article-title":"Transdermal therapeutic systems containing crystallization inhibitors, WO 93\/08795, Schering AG","volume":"119","author":"Lipp","year":"1993","journal-title":"Chem Abstr."},{"key":"2024103110030301300_cit8","first-page":"672","article-title":"Rational design of prodrugs for matrix-type transdermal delivery systems: gestodene esters","volume":"22","author":"Lipp","year":"1995","journal-title":"Proc. Int. Symp. Contr. Rel. Bioact. Mater."},{"key":"2024103110030301300_cit9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0378-5173(96)04647-9","article-title":"Control of drug crystallization in transdermal matrix system","volume":"142","author":"Ma","year":"1996","journal-title":"Int. J. Pharm."},{"key":"2024103110030301300_cit10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0168-3659(96)01595-7","article-title":"The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro","volume":"46","author":"Pellet","year":"1997","journal-title":"J. Contr. Rel. Bioact. Mater."},{"key":"2024103110030301300_cit11","first-page":"128","volume-title":"Crystal Growth from Melts: Application to Growth of Groups 1 and Groups 2 Crystals","author":"Roy","year":"1992"},{"key":"2024103110030301300_cit12","first-page":"703","article-title":"Crystallization in NETA-17\u03b2-E2 Proc","volume":"24","author":"Stefano","year":"1997","journal-title":"Int. Symp. Contr. Rel. Bioact. Mater."},{"volume-title":"Use of polymer additives to inhibit phenytoin nucleation and crystal growth from supersaturated aqueous solution","year":"1994","author":"Yeoh","key":"2024103110030301300_cit13"},{"key":"2024103110030301300_cit14","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3109\/03639049109048057","article-title":"Transdermal dualcontrolled delivery of testosterone and estradiol: (I) impact of system design","volume":"17","author":"Yu","year":"1991","journal-title":"Drug. Dev. Ind. Pharm."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.1998.tb03357.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/50\/12\/1343\/60262134\/j.2042-7158.1998.tb03357.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/50\/12\/1343\/60262134\/j.2042-7158.1998.tb03357.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:33:47Z","timestamp":1730370827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/50\/12\/1343\/6152794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12,1]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[1998,12,1]]},"published-print":{"date-parts":[[1998,12,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.1998.tb03357.x","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[1998,12]]},"published":{"date-parts":[[1998,12,1]]}}}